Arrowhead Net Income From Continuing Ops from 2010 to 2026
| HDP1 Stock | EUR 55.08 0.16 0.29% |
Net Income From Continuing Ops | First Reported 2017-03-31 | Previous Quarter 16.1 M | Current Value 28.2 M | Quarterly Volatility 94.4 M |
Check Arrowhead Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arrowhead Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 107.9 M, Selling General Administrative of 147.2 M or Total Revenue of 1 B, as well as many indicators such as . Arrowhead financial statements analysis is a perfect complement when working with Arrowhead Pharmaceuticals Valuation or Volatility modules.
Arrowhead | Net Income From Continuing Ops |
The Net Income From Continuing Ops trend for Arrowhead Pharmaceuticals offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Arrowhead Pharmaceuticals is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Arrowhead Pharmaceuticals' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Arrowhead Pharmaceuticals over the last few years. It is Arrowhead Pharmaceuticals' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arrowhead Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Arrowhead Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (91,813,256) | |
| Coefficient Of Variation | (165.44) | |
| Mean Deviation | 90,047,012 | |
| Median | (58,725,412) | |
| Standard Deviation | 151,900,067 | |
| Sample Variance | 23073.6T | |
| Range | 677.7M | |
| R-Value | (0.16) | |
| Mean Square Error | 24016.5T | |
| R-Squared | 0.02 | |
| Significance | 0.55 | |
| Slope | (4,678,610) | |
| Total Sum of Squares | 369178.1T |
Arrowhead Net Income From Continuing Ops History
About Arrowhead Pharmaceuticals Financial Statements
Arrowhead Pharmaceuticals stakeholders use historical fundamental indicators, such as Arrowhead Pharmaceuticals' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although Arrowhead Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Arrowhead Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Arrowhead Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Arrowhead Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 27.1 M | 28.5 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Arrowhead Pharmaceuticals Correlation against competitors. For more detail on how to invest in Arrowhead Stock please use our How to Invest in Arrowhead Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.